The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts that provides advice to the Centers for Disease Control and Prevention (CDC), normally meets three times per year to develop US vaccine recommendations. The ACIP met June 21–23, 2023, to discuss respiratory syncytial virus (RSV) vaccines, influenza vaccines, pneumococcal vaccines, meningococcal vaccines, and COVID-19 vaccines. The ACIP also held a special meeting on August 3, 2023 to discuss RSV prophylaxis in infants. This update summarizes the proceedings of these meetings that are most relevant to the pediatric population. Major updates for pediatric clinicians include a new recommendation for the monoclonal antibody nirsevimab for prevention of RSV disease in all infants, recommendations regarding use of 20-valent pneumococcal conjugate vaccine (PCV20), and discussion of potential forthcoming changes to meningococcal and COVID-19 vaccination recommendations.
CONFLICT OF INTEREST DISCLOSURES: S.T.O. has no relevant financial disclosures. A.B.Y participates in COVID-19 and Lyme vaccine trials sponsored by Pfizer and her institution receives funds to conduct these trials. C.G.A participated in COVID-19 vaccine trials sponsored by Moderna and her institution receives funds to conduct the trial. D.W.K. was an investigator for a study of remdesivir in children sponsored by Gilead that is now closed. His institution received funds to participate in the study. G.C.P. participates in COVID-19 vaccine trials sponsored by Pfizer and Moderna and his institution receives funds to conduct these trials.